title: Hypoxia increases androgen receptor activity in prostate cancer cells.
abstract: Recent studies show that prostate cancer cells are able to survive in a hypoxic tumor environment, and the extent of tumor hypoxia correlates with poor clinical outcome. Androgen deprivation, the most common form of prostate cancer therapy, was itself shown to induce a state of transient hypoxia at the microenvironmental level. Because androgen receptor (AR) signaling plays a critical role in prostate cancer, we investigated the effect of hypoxia in regulating AR function. We found that in LNCaP prostate cancer cells, AR binding to the androgen-responsive element (ARE), prostate-specific antigen accumulation, and ARE-reporter gene activity were increased after hypoxia treatment. Hypoxia-enhanced AR function was also observed when AR was exogenously introduced into AR-null DU145 cells. Confocal microscopy and chromatin immunoprecipitation assays showed that AR translocation to the nucleus and AR recruitment to the prostate-specific antigen promoter were facilitated after hypoxia treatment. The AR stimulatory effect seemed to be ligand-dependent because it was abrogated when cells were cultured in an androgen-depleted medium, but was restored with the addition of R1881, a synthetic androgen. The sensitivity of AR activation to R1881 was also increased after hypoxia treatment. Although concentrations of <1 nmol/L R1881 did not induce ARE reporter activity under normoxic conditions, exposure to hypoxia greatly potentiated the AR response to low levels of R1881. Collectively, our results provide compelling evidence that changes in hypoxia/reoxygenation stimulate AR trans-activation and sensitization. The AR-stimulatory effect of an unstable tissue oxygenation milieu of a tumor is likely to contribute to treatment resistance and the emergence of recurrent prostate cancer.
authors.affiliation: Department of Cell Stress Biology, Roswell Park Cancer Institute, Buffalo, New York 14263, USA.
authors.forename: Soo-Yeon
authors.initials: SY
authors.lastname: Park
authors.forename: Yun-Jeong
authors.initials: YJ
authors.lastname: Kim
authors.forename: Allen C
authors.initials: AC
authors.lastname: Gao
authors.forename: James L
authors.initials: JL
authors.lastname: Mohler
authors.forename: Sergio A
authors.initials: SA
authors.lastname: Onate
authors.forename: Alejandro A
authors.initials: AA
authors.lastname: Hidalgo
authors.forename: Clement
authors.initials: C
authors.lastname: Ip
authors.forename: Eun-Mi
authors.initials: EM
authors.lastname: Park
authors.forename: Sun Young
authors.initials: SY
authors.lastname: Yoon
authors.forename: Young-Mee
authors.initials: YM
authors.lastname: Park
mesh_terms: D015687:Cell Hypoxia; D045744:Cell Line, Tumor; D002467:Cell Nucleus / Q000378:metabolism; D006801:Humans; D008297:Male; D011401:Promoter Regions, Genetic; D011471:Prostatic Neoplasms / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D011944:Receptors, Androgen / Q000096:biosynthesis / Q000235:genetics / Q000378:metabolism*; D020218:Response Elements; D015533:Transcriptional Activation; D014162:Transfection
chemical_list: D011944:Receptors, Androgen